null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal long-term debt; relies primarily on equity financing and grants; leverage ratio near zero, limiting interest burden but signaling cash burn dependency.

Negligible direct interest rate sensitivity; no significant variable-rate debt; rising rates increase cost of future equity dilution and reduce biotech investor appetite.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Key chokepoints: (1) API (active pharmaceutical ingredient) sourcing from India/China for gut microbiome therapies; (2) clinical-grade reagent supply via limited US/EU vendors.

Essentially US-only clinical-stage company; no meaningful international revenue; sovereign currency devaluation exposure is effectively null.

Operations concentrated in the United States; no disclosed international revenue markets; currency devaluation risk is not applicable at current stage.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or few CROs (contract research organizations) for clinical trials; substitution mid-trial would delay timelines by 12–24 months and increase costs materially.

Clinical-stage biopharmaceutical; no cloud-dependent commercial product; AWS/GCP/Azure termination would affect data/analytics ops but not core drug development pipeline.

Secondary model is partnership/licensing; cloud termination would disrupt data sharing with partners but is non-fatal; data portability risk is moderate.

Low API coupling risk to tech platforms; primary switching risk lies in clinical trial infrastructure (CRO, site networks), not software APIs.

Low Howey Test risk; revenue model is drug development/licensing, not token or investment-contract-based; equity securities are standard registered shares.

Very High

Limited GDPR/CCPA exposure; clinical trial data governed by FDA/ICH GCP standards; patient data handling creates HIPAA risk but international data sovereignty exposure is minimal.

Low antitrust exposure; niche gut microbiome/NASH therapeutic space with no dominant market position; no horizontal merger activity flagged.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Effectively 0% recurring commercial revenue; company is pre-revenue/clinical-stage; income derives from grants, partnerships, and potential milestone payments (transactional).

Monetization via future drug royalties, licensing milestones, and potential acquisition; no SaaS or subscription vector; entirely outcome-contingent.

No commercial pricing architecture yet; future drug pricing will be subject to payer negotiations, CMS/Medicare drug pricing pressure, and rare-disease premium benchmarks.

Potential moderate-to-high pricing power if therapies achieve first-in-class or orphan designation; NASH market competition could compress pricing significantly.

Target gross margins for approved biologics/small molecules typically 70–85%; not yet applicable but structurally achievable if commercialized.

No free-rider leakage problem applicable; pre-commercial stage; clinical trial patient retention (dropout rate) is the analogous churn metric, typically 10–20% in GI trials.

Headcount-linear at current scale; small team (~10–30 employees); revenue growth will require proportional R&D and commercial headcount additions until licensing deals scale.

Marginal cost of growth is high and capital-intensive; each new clinical indication requires $5M–$50M+ in trial costs; no software-like scalability.

Not applicable; BioVie does not operate a franchise network.

At 10x scale (post-approval), CAC shifts to physician/hospital detailing; typical pharma CAC per prescriber ranges $500–$5,000; payer access is the binding constraint.

No meaningful network effects; drug efficacy is not enhanced by user volume; competitive moat relies on IP exclusivity and clinical data packages.

AI displacement risk is low for core drug discovery; AI could accelerate biomarker identification and trial design, reducing R&D cost 10–20% but not displacing the business.

Moderate recession resilience; NASH and ascites are serious unmet medical needs with inelastic demand, but funding access and payer coverage tighten in downturns.

Primary future customer: hospital systems and gastroenterology/hepatology specialty practices treating NASH, ascites, and neurological conditions.

Secondary customers: government/institutional payers (Medicare, Medicaid) and specialty pharmacy distributors; concentration risk high if single payer dominates reimbursement.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is allocated almost entirely to clinical-stage R&D (forward-looking); no legacy infrastructure to maintain; burn rate ~$1–5M/quarter based on disclosed financials.

0001580149

BIVI